Sarepta Q3 2025: Context, Correction, and What Comes Next

In this newsletter, we set the context for where Sarepta stands today. We begin with a short video that distills our earlier coverage of Elevidys and the safety challenges that reshaped the company’s gene therapy program for Duchenne muscular dystrophy.

We then walk through Sarepta’s Q3 2025 results and presentation to assess whether management is genuinely resolving the regulatory and commercial issues around Elevidys—and what still remains uncertain.

In the next installment, we will turn to the company’s financial footing and whether Sarepta is moving closer to a sustainable operating structure.

Framing the Story: Why This Video Matters Before the Q3 Breakdown

Before unpacking Q3, it’s worth revisiting how the company arrived at this moment. The AI-generated recap video—built from our earlier newsletters—captures a difficult year marked by clinical setbacks, FDA intervention, internal restructuring, and a broader loss of confidence in a platform once viewed as a leader in genetic medicine.

The video also revisits the underlying biology: how hepatic vulnerability in DMD patients created conditions for AAV-related toxicity, why this was not simply a “vector problem,” and how regulatory expectations evolved in real time.

This backdrop is important because Q3 was not just another quarterly update; it represented the first meaningful attempt to rebuild credibility after a year of scientific, regulatory, and organizational pressure.

Watching the video first helps anchor the major questions that shaped the Q3 call—Elevidys’ regulatory future, the role of sirolimus in non-ambulatory patients, the PMO confirmatory path, RNAi optionality, and whether the new cost structure can hold.

Put simply: the video frames the stakes. It captures the sequence of events and the scale of the challenge, enabling the Q3 discussion to be assessed with clearer context.

Video generated using Symvol Lumina 3.5 model